Valbiotis presents the OLALIP clinical study at the European Association of Preventive Cardiology (EAPC) Congress of the European Society of Cardiology (ESC), the leading community for healthcare professionals involved in preventive cardiology (April 25-27 2024 in Athens, Greece).
This presentation details the protocol as well as the results obtained, during an oral session. The OLALIP study constitutes clinical proof of the effect of Lipidrive®, the active ingredient in Valbiotis®PRO Cholesterol, on the reduction of LDL cholesterol at a dose of 2.5 grams per day and over a period of 6 weeks.
See the poster